ABVC - American BriVision issues Phase 2 data in ADHD trial

Issuing a clinical study report of the Phase II Part I clinical trial for ABV-1505 in adult Attention-Deficit Hyperactivity Disorder, the clinical-stage biopharma company, American BriVision (ABVC) said it expected to commence the Phase II Part II trial in Q2 2021.Following encouraging Phase II trial in major depressive disorder for its active ingredient PDC-1421, the treatment was expanded into adult ADHD trials.It was safe, well-tolerated, and efficacious during its treatment and follow-up period with six adult patients, the company said in a statement.Both low and high doses have met the primary endpoints passing the required 40% population in ADHD-RS-IV test scores.Expressing satisfaction over the clinical results for both low and high doses, Dr. Howard Doong, the CEO of American BriVision, said the company expected to commence the Phase II Part II trial for ABV-1505 in Q2 2021 in UCSF and major medical centers in Taiwan. Studies suggest that 4% of adults suffer from ADHD,

For further details see:

American BriVision issues Phase 2 data in ADHD trial